Anuh Pharma Limited AI Stock Analysis
Want to see IN:ANUHPHR full AI Analyst Report?
Anuh Pharma Limited (ANUHPHR) AI Stock Analysis
Anuh Pharma Limited
(NSE:ANUHPHR)
The score is primarily held back by weaker FY2026 fundamentals—margin compression and especially negative operating/free cash flow—despite the strong, near-zero debt balance sheet and solid revenue growth. Technicals are moderately supportive with the stock trading above major moving averages, while valuation is reasonable but not distinctly attractive.
Anuh Pharma Limited (ANUHPHR) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 8.26B
- Dividend Yield
- 1.82%
- Average Volume (3M)
- 17.82K
- Price to Earnings (P/E)
- 17.3
- Beta (1Y)
- 0.50
- Revenue Growth
- 6.62%
- EPS Growth
- 53.57%
- Country
- India
- Employees
- 323
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Anuh Pharma Limited Business Overview & Revenue Model
Company Description
Anuh Pharma Ltd. is an Indian enterprise specializing in the manufacturing and distribution of bulk drugs and various chemical compounds. The company provides a comprehensive selection of active pharmaceutical ingredients (APIs), encompassing macroli...
How the Company Makes Money
Anuh Pharma Limited primarily makes money by selling active pharmaceutical ingredients (APIs) and related bulk drug products to customers such as pharmaceutical formulation companies and other drug manufacturers. Revenue is recognized from the sale o...
Anuh Pharma Limited Financial Statement Overview
Summary
Revenue growth is strong and the balance sheet is exceptionally low-debt (high financial flexibility), but FY2026 profitability weakened (gross and net margin compression) and cash generation deteriorated sharply with negative operating and free cash flow, raising near-term cash-conversion concerns.
Income Statement
62PositiveBalance Sheet
88Very PositiveCash Flow
34Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.84B | 7.72B | 6.62B | 6.47B | 5.27B | 4.87B |
| Gross Profit | 910.30M | 1.34B | 1.62B | 1.60B | 1.26B | 1.09B |
| EBITDA | 329.27M | 660.76M | 703.64M | 872.47M | 573.89M | 520.43M |
| Net Income | 200.69M | 410.46M | 473.52M | 600.58M | 361.80M | 305.61M |
Balance Sheet | ||||||
| Total Assets | 5.09B | 5.57B | 5.07B | 4.46B | 4.05B | 3.47B |
| Cash, Cash Equivalents and Short-Term Investments | 135.33M | 531.61M | 734.15M | 622.56M | 530.77M | 252.65M |
| Total Debt | 2.27M | 583.00K | 108.86M | 26.93M | 9.07M | 42.23M |
| Total Liabilities | 1.82B | 2.05B | 1.81B | 1.54B | 1.64B | 1.33B |
| Stockholders Equity | 3.27B | 3.52B | 3.26B | 2.91B | 2.41B | 2.14B |
Cash Flow | ||||||
| Free Cash Flow | -58.52M | -108.42M | 169.79M | 79.08M | 523.51M | 272.49M |
| Operating Cash Flow | 121.88M | -29.73M | 371.25M | 129.25M | 539.02M | 288.64M |
| Investing Cash Flow | 162.28M | 172.97M | -199.09M | 9.18M | -434.84M | -78.17M |
| Financing Cash Flow | -294.46M | -258.22M | -48.60M | -85.68M | -122.87M | -194.49M |
Anuh Pharma Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ANUHPHR, the sentiment is Neutral. The current price of 82.52 is above the 20-day moving average (MA) of 81.66, below the 50-day MA of 85.53, and above the 200-day MA of 79.07, indicating a neutral trend. The MACD of -0.42 indicates Negative momentum. The RSI at 48.96 is Neutral, neither overbought nor oversold. The STOCH value of 31.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ANUHPHR.
Anuh Pharma Limited Peers Comparison
Overall Rating
IN:KILITCH63Neutral
IN:ANUHPHR61Neutral
IN:ZIMLAB60Neutral
IN:WANBURY56Neutral
IN:ALBERTDAVD54Neutral
IN:SIGACHI47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 63Neutral | INR 7.53B | 30.88 | ― | ― | 13.87% | -17.80% | |
| 61Neutral | INR 8.27B | 17.30 | ― | 1.82% | 6.62% | 53.57% | |
| 60Neutral | INR 7.60B | 263.30 | ― | ― | 13.14% | -60.77% | |
| 56Neutral | INR 6.77B | 12.69 | ― | ― | 7.45% | -6.56% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | INR 4.48B | 15.52 | ― | 0.63% | 19.69% | ― | |
| 47Neutral | INR 10.88B | 43.65 | ― | 0.35% | -3.07% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ANUHPHR | Anuh Pharma Limited | 82.52 | 3.43 | 4.34% | |
| IN:ALBERTDAVD | Albert David Ltd | 785.00 | -16.43 | -2.05% | |
| IN:KILITCH | Kilitch Drugs (India) Limited | 215.40 | 37.83 | 21.30% | |
| IN:SIGACHI | Sigachi Industries Limited | 28.47 | -6.53 | -18.65% | |
| IN:WANBURY | Wanbury Limited | 193.65 | -39.25 | -16.85% | |
| IN:ZIMLAB | Zim Laboratories Ltd. | 141.70 | 67.79 | 91.72% |
Anuh Pharma Limited Corporate Events
Anuh Pharma Challenges Income Tax Demand Order for FY 2018-19
Anuh Pharma Limited has received a demand order from the Income Tax Department for the assessment year 2018-19, citing disallowance of certain deductions and raising a tax demand of Rs 9,93,206. The company plans to appeal the order before the Commis...
Anuh Pharma Clears Board Reappointments, Auditor Mandate and Governance Overhaul
Anuh Pharma Limited has approved several management and governance changes at its 66th Annual General Meeting, including the reappointment of non-executive non-independent directors Bipin Nemchand Shah and Arun Lalchand Todarwal. The meeting also con...
Anuh Pharma Shareholders Clear Board Reappointments and Governance Updates
Anuh Pharma Limited has reported that shareholders at its 66th Annual General Meeting approved the reappointment of two non-executive non-independent directors and the cost auditor for the financial year ending March 2027. The company also approved r...
Anuh Pharma Publishes Q1 FY27 Unaudited Results in Newspapers
Anuh Pharma Limited has published newspaper notices announcing the availability of its unaudited financial results for the quarter ended 30 June 2026. The results were carried in the Financial Express (English) and Mumbai Lakshdeep (Marathi) on 9 Aug...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026
